Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation

Saved in:
Bibliographic Details
Published in:Blood cancer journal (New York) 2013-08, Vol.3 (8), p.e136-e136
Main Authors: Schönefeldt, C, Sockel, K, Wehner, R, Sopper, S, Wolf, D, Wermke, M, Thiede, C, Oelschlägel, U, Ehninger, G, Bornhäuser, M, Platzbecker, U, Schmitz, M
Format: Article
Language:English
Subjects:
631/250/1619/382
692/699/1541
692/700/565/1436
692/700/565/545/576/1955
Biomedical and Life Sciences
Biomedicine
Cancer Research
Hematology
Letter to the Editor
Oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c376t-eaf53beb8baa90115b642408fc350a33a4842e5fc9fa186f8359033dd3a430203
cites cdi_FETCH-LOGICAL-c376t-eaf53beb8baa90115b642408fc350a33a4842e5fc9fa186f8359033dd3a430203
container_end_page e136
container_issue 8
container_start_page e136
container_title Blood cancer journal (New York)
container_volume 3
creator Schönefeldt, C
Sockel, K
Wehner, R
Sopper, S
Wolf, D
Wermke, M
Thiede, C
Oelschlägel, U
Ehninger, G
Bornhäuser, M
Platzbecker, U
Schmitz, M
description
doi_str_mv 10.1038/bcj.2013.35
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3763388</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1429633229</sourcerecordid><originalsourceid>FETCH-LOGICAL-c376t-eaf53beb8baa90115b642408fc350a33a4842e5fc9fa186f8359033dd3a430203</originalsourceid><addsrcrecordid>eNptkV9rFDEUxQdRbKl98l0Cvgg6azKZbJMXYWm1irsK_nkOdzJ3xiwzyZhkCuvH8BM3y9ayinlJ4Pxyzr2conjK6IJRLl83ZruoKOMLLh4UpxWt61JwKR4evU-K8xi3NB-xZIqpx8VJxZUStBanxe_VLzC7ZFvrkNhxAhsi-fSRGBwGAibZG5t2xDqy2qwJuJZsrr6SCZJFlyKZXYuh99b1ZPPlqmwgYkumgCWOU_6KJAWENGaWQJcwEBgG36NDa0hMOB5iUgAXpwFcyr7ePSkedTBEPL-7z4rv795-u3xfrj9ff7hcrUvDL5apROgEb7CRDYCijIlmWVc1lZ3hggLnUMu6QtEZ1QGTy05yoSjnbZsVTivKz4o3B99pbkZsTZ4ywKCnYEcIO-3B6r8VZ3_o3t_oHM-5lNngxZ1B8D9njEmPNu43Aod-jprVlcpkVamMPv8H3fo5uLyeZheyVrkQuadeHigTfIwBu_thGNX7unWuW-_r1lxk-tnx_Pfsn3Iz8OoAxCy5HsNR6H_8bgFFiLZ-</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1784923989</pqid></control><display><type>article</type><title>Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Schönefeldt, C ; Sockel, K ; Wehner, R ; Sopper, S ; Wolf, D ; Wermke, M ; Thiede, C ; Oelschlägel, U ; Ehninger, G ; Bornhäuser, M ; Platzbecker, U ; Schmitz, M</creator><creatorcontrib>Schönefeldt, C ; Sockel, K ; Wehner, R ; Sopper, S ; Wolf, D ; Wermke, M ; Thiede, C ; Oelschlägel, U ; Ehninger, G ; Bornhäuser, M ; Platzbecker, U ; Schmitz, M</creatorcontrib><identifier>ISSN: 2044-5385</identifier><identifier>EISSN: 2044-5385</identifier><identifier>DOI: 10.1038/bcj.2013.35</identifier><identifier>PMID: 23995045</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/250/1619/382 ; 692/699/1541 ; 692/700/565/1436 ; 692/700/565/545/576/1955 ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Hematology ; Letter to the Editor ; Oncology</subject><ispartof>Blood cancer journal (New York), 2013-08, Vol.3 (8), p.e136-e136</ispartof><rights>The Author(s) 2013</rights><rights>Copyright Nature Publishing Group Aug 2013</rights><rights>Copyright © 2013 Macmillan Publishers Limited 2013 Macmillan Publishers Limited</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c376t-eaf53beb8baa90115b642408fc350a33a4842e5fc9fa186f8359033dd3a430203</citedby><cites>FETCH-LOGICAL-c376t-eaf53beb8baa90115b642408fc350a33a4842e5fc9fa186f8359033dd3a430203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1784923989/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1784923989?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23995045$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schönefeldt, C</creatorcontrib><creatorcontrib>Sockel, K</creatorcontrib><creatorcontrib>Wehner, R</creatorcontrib><creatorcontrib>Sopper, S</creatorcontrib><creatorcontrib>Wolf, D</creatorcontrib><creatorcontrib>Wermke, M</creatorcontrib><creatorcontrib>Thiede, C</creatorcontrib><creatorcontrib>Oelschlägel, U</creatorcontrib><creatorcontrib>Ehninger, G</creatorcontrib><creatorcontrib>Bornhäuser, M</creatorcontrib><creatorcontrib>Platzbecker, U</creatorcontrib><creatorcontrib>Schmitz, M</creatorcontrib><title>Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation</title><title>Blood cancer journal (New York)</title><addtitle>Blood Cancer Journal</addtitle><addtitle>Blood Cancer J</addtitle><subject>631/250/1619/382</subject><subject>692/699/1541</subject><subject>692/700/565/1436</subject><subject>692/700/565/545/576/1955</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Hematology</subject><subject>Letter to the Editor</subject><subject>Oncology</subject><issn>2044-5385</issn><issn>2044-5385</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptkV9rFDEUxQdRbKl98l0Cvgg6azKZbJMXYWm1irsK_nkOdzJ3xiwzyZhkCuvH8BM3y9ayinlJ4Pxyzr2conjK6IJRLl83ZruoKOMLLh4UpxWt61JwKR4evU-K8xi3NB-xZIqpx8VJxZUStBanxe_VLzC7ZFvrkNhxAhsi-fSRGBwGAibZG5t2xDqy2qwJuJZsrr6SCZJFlyKZXYuh99b1ZPPlqmwgYkumgCWOU_6KJAWENGaWQJcwEBgG36NDa0hMOB5iUgAXpwFcyr7ePSkedTBEPL-7z4rv795-u3xfrj9ff7hcrUvDL5apROgEb7CRDYCijIlmWVc1lZ3hggLnUMu6QtEZ1QGTy05yoSjnbZsVTivKz4o3B99pbkZsTZ4ywKCnYEcIO-3B6r8VZ3_o3t_oHM-5lNngxZ1B8D9njEmPNu43Aod-jprVlcpkVamMPv8H3fo5uLyeZheyVrkQuadeHigTfIwBu_thGNX7unWuW-_r1lxk-tnx_Pfsn3Iz8OoAxCy5HsNR6H_8bgFFiLZ-</recordid><startdate>20130830</startdate><enddate>20130830</enddate><creator>Schönefeldt, C</creator><creator>Sockel, K</creator><creator>Wehner, R</creator><creator>Sopper, S</creator><creator>Wolf, D</creator><creator>Wermke, M</creator><creator>Thiede, C</creator><creator>Oelschlägel, U</creator><creator>Ehninger, G</creator><creator>Bornhäuser, M</creator><creator>Platzbecker, U</creator><creator>Schmitz, M</creator><general>Nature Publishing Group UK</general><general>Springer Nature B.V</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130830</creationdate><title>Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation</title><author>Schönefeldt, C ; Sockel, K ; Wehner, R ; Sopper, S ; Wolf, D ; Wermke, M ; Thiede, C ; Oelschlägel, U ; Ehninger, G ; Bornhäuser, M ; Platzbecker, U ; Schmitz, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c376t-eaf53beb8baa90115b642408fc350a33a4842e5fc9fa186f8359033dd3a430203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>631/250/1619/382</topic><topic>692/699/1541</topic><topic>692/700/565/1436</topic><topic>692/700/565/545/576/1955</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Hematology</topic><topic>Letter to the Editor</topic><topic>Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schönefeldt, C</creatorcontrib><creatorcontrib>Sockel, K</creatorcontrib><creatorcontrib>Wehner, R</creatorcontrib><creatorcontrib>Sopper, S</creatorcontrib><creatorcontrib>Wolf, D</creatorcontrib><creatorcontrib>Wermke, M</creatorcontrib><creatorcontrib>Thiede, C</creatorcontrib><creatorcontrib>Oelschlägel, U</creatorcontrib><creatorcontrib>Ehninger, G</creatorcontrib><creatorcontrib>Bornhäuser, M</creatorcontrib><creatorcontrib>Platzbecker, U</creatorcontrib><creatorcontrib>Schmitz, M</creatorcontrib><collection>SpringerOpen</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood cancer journal (New York)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schönefeldt, C</au><au>Sockel, K</au><au>Wehner, R</au><au>Sopper, S</au><au>Wolf, D</au><au>Wermke, M</au><au>Thiede, C</au><au>Oelschlägel, U</au><au>Ehninger, G</au><au>Bornhäuser, M</au><au>Platzbecker, U</au><au>Schmitz, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation</atitle><jtitle>Blood cancer journal (New York)</jtitle><stitle>Blood Cancer Journal</stitle><addtitle>Blood Cancer J</addtitle><date>2013-08-30</date><risdate>2013</risdate><volume>3</volume><issue>8</issue><spage>e136</spage><epage>e136</epage><pages>e136-e136</pages><issn>2044-5385</issn><eissn>2044-5385</eissn><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>23995045</pmid><doi>10.1038/bcj.2013.35</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2044-5385
ispartof Blood cancer journal (New York), 2013-08, Vol.3 (8), p.e136-e136
issn 2044-5385
2044-5385
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3763388
source Open Access: PubMed Central; Publicly Available Content Database; Springer Nature - nature.com Journals - Fully Open Access
subjects 631/250/1619/382
692/699/1541
692/700/565/1436
692/700/565/545/576/1955
Biomedical and Life Sciences
Biomedicine
Cancer Research
Hematology
Letter to the Editor
Oncology
title Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T04%3A03%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Azacytidine%20impairs%20NK%20cell%20activity%20in%20AML%20and%20MDS%20patients%20undergoing%20MRD-based%20pre-emptive%20treatment%20after%20allogeneic%20stem%20cell%20transplantation&rft.jtitle=Blood%20cancer%20journal%20(New%20York)&rft.au=Sch%C3%B6nefeldt,%20C&rft.date=2013-08-30&rft.volume=3&rft.issue=8&rft.spage=e136&rft.epage=e136&rft.pages=e136-e136&rft.issn=2044-5385&rft.eissn=2044-5385&rft_id=info:doi/10.1038/bcj.2013.35&rft_dat=%3Cproquest_pubme%3E1429633229%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c376t-eaf53beb8baa90115b642408fc350a33a4842e5fc9fa186f8359033dd3a430203%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1784923989&rft_id=info:pmid/23995045&rfr_iscdi=true